Financial Overview - The total assets of Yifan Pharmaceutical Co., Ltd. increased from CNY 12,285,788,088.75 at the beginning of the period to CNY 12,674,139,895.70 at the end, representing a growth of approximately 3.17% [1][2] - Total liabilities rose from CNY 3,858,992,750.77 to CNY 4,017,412,350.66, indicating an increase of about 4.1% [2][3] - The total equity increased from CNY 8,426,795,337.98 to CNY 8,656,727,545.04, reflecting a growth of approximately 2.72% [2][3] Income Statement Highlights - The total operating revenue for the first half of 2025 was CNY 2,635,110,083.18, slightly up from CNY 2,632,089,783.35 in the same period of 2024 [3][4] - Total operating costs decreased from CNY 2,363,162,281.95 to CNY 2,316,453,207.97, showing a reduction of about 1.98% [4] - Net profit for the first half of 2025 was CNY 284,158,135.82, compared to CNY 212,445,979.23 in the first half of 2024, marking an increase of approximately 33.8% [4][5] Cash Flow Analysis - Net cash flow from operating activities improved significantly, rising from CNY 143,774,218.95 in the first half of 2024 to CNY 286,097,071.23 in the first half of 2025 [5] - Cash flow from investing activities showed a net outflow of CNY 159,041,410.09, compared to a larger outflow of CNY 195,466,241.92 in the previous year [5] - Cash flow from financing activities resulted in a net outflow of CNY 147,413,242.53, contrasting with a net inflow of CNY 207,793,148.58 in the first half of 2024 [5] Balance Sheet Insights - Current assets totaled CNY 3,967,724,843.29 at the end of the period, up from CNY 3,778,271,166.02 at the beginning, indicating a growth of approximately 5.03% [1][2] - Non-current assets increased from CNY 8,507,516,922.73 to CNY 8,706,415,052.41, reflecting a growth of about 2.34% [1][2] - The company's cash and cash equivalents decreased from CNY 889,388,507.75 to CNY 785,909,109.30, a decline of approximately 11.6% [1][2]

Meeting Announcement - Yifan Pharmaceutical Co., Ltd. will hold its second extraordinary general meeting of shareholders for 2025 on September 5, 2025 [1][2] - The meeting will start at 1:30 PM and will include both on-site and online voting options [1][2] Voting Procedures - Shareholders can vote either in person or through the Shenzhen Stock Exchange trading system and internet voting system, but must choose one method [2][5] - The online voting will be available from 9:15 AM to 11:30 AM and from 1:00 PM to 3:00 PM on the same day [1][2] Eligibility and Registration - All ordinary shareholders registered by the close of business on August 29, 2025, are eligible to attend and vote [2][4] - Registration can be done via on-site, mail, or fax before August 29, 2025 [4] Agenda Items - The meeting will include proposals that require a two-thirds majority vote from attending shareholders for special resolutions [3][4] - Proposals include amendments to the company's articles of association and the election of directors [3][4] Contact Information - For inquiries, shareholders can contact Feng Dexi or Li Lei at the provided phone numbers and email [4]

证券代码：002019 证券简称：亿帆医药 公告编号：2025-047 亿帆医药股份有限公司 独立董事候选人声明与承诺 声明人曾玉红作为亿帆医药股份有限公司第九届董事会独立董事候选人， 已充分了解并同意由提名人亿帆医药股份有限公司董事会提名为亿帆医药股 份有限公司（以下简称"该公司"）第九届董事会独立董事候选人。现公开声 明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关 法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 如否，请详细说明： 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定的独立董事任职资格和条件。 ? 是 □否 如否，请详细说明： ? 是 □否 如否，请详细说明： 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任 公司董事的情形。 四、本人符合该公司章程规定的独立董事任职条件。 ? 是 □否 ? 是 □否 一、本人已经通过亿帆医药股份有限公司第九届董事会提名委员会或者独 立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独 立履职情 ...

亿帆医药股份有限公司 | | 编制单位：亿帆医药股份有限公司 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 单位：万元 | | | | | | | | | | | | | | | | 占用方与上市公 | 上市公司核算 | 2025 年期初占用 | | 计 | 2025 年 | 1-6 月占用 | 2025 年 | 1-6 月偿 | | 还 2025 年 | 6 月 | 30 | | | | | | | | | | | | 非经营性资金占用 | | 资金占用方名 | | | | | | | | | | 称 | | | | | | | | | 占用形成原因 | 占用性质 | | | | | | 司的关联关系 | 的会计科目 | 资金余额 | | 发生金额（不含利 | | 资金的利息(如有) | | 累计发 | | 生金额 | 日占用资金余额 | | | | | | | | | | | | | | | | | | 息） | | | | | | | | 控股股东、实际控 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2025-048 亿帆医药股份有限公司 独立董事候选人声明与承诺 声明人刘梅娟作为亿帆医药股份有限公司第九届董事会独立董事候选人， 已充分了解并同意由提名人亿帆医药股份有限公司董事会提名为亿帆医药股 份有限公司（以下简称"该公司"）第九届董事会独立董事候选人。现公开声 明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关 法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 如否，请详细说明： 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任 公司董事的情形。 ? 是 □否 一、本人已经通过亿帆医药股份有限公司第九届董事会提名委员会或者独 立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独 立履职情形的密切关系。 ? 是 □否 如否，请详细说明： 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定的独立董事任职资格和条件。 ? 是 □否 如否，请详细说明： 四、本人符合该公司章程规定的独立董事任职条件。 ...

Core Viewpoint - The company is revising its Articles of Association to align with updated legal regulations and its operational realities, which will be submitted for shareholder approval [1]. Summary by Sections Company Structure and Governance - The company is established as a joint-stock limited company in accordance with the Company Law and other relevant regulations [2]. - The legal representative of the company will be the president, who is elected by the board of directors [3]. Amendments to Articles of Association - The first article has been amended to include employees alongside shareholders and creditors in protecting their legal rights [1]. - New provisions have been added to clarify the responsibilities of the legal representative and the company's liability for civil activities conducted in its name [4]. Shareholder Rights and Responsibilities - Shareholders are entitled to rights based on their shareholdings, including profit distribution and participation in decision-making processes [12]. - Shareholders holding more than 5% of shares must report any pledging of their shares to the company [39]. Capital Structure and Share Issuance - The total number of shares issued by the company is 1,216,390,085, all of which are ordinary shares [7]. - The company can increase its capital through various methods, including public offerings and private placements, subject to shareholder approval [8]. Share Repurchase and Financial Assistance - The company may repurchase its shares through public trading or other legally recognized methods, with specific conditions outlined for different scenarios [9][10]. - Financial assistance for acquiring shares is limited to 10% of the total issued capital [7]. Shareholder Meetings and Decision-Making - The company’s shareholder meetings are the highest authority, responsible for major decisions such as approving financial reports and capital changes [21]. - Specific conditions are set for convening extraordinary shareholder meetings, including significant losses or requests from major shareholders [23]. Compliance and Legal Obligations - The company and its controlling shareholders must adhere to legal obligations and maintain transparency in operations, including timely disclosure of significant events [19][20].

Core Points - The company held the third meeting of the 2022 employee stock ownership plan on August 14, 2025, to discuss adjustments to the management committee [1] - The meeting approved the election of Mr. Zhou Qin to the management committee following the resignation of Ms. Qian Liping due to a job adjustment [1] - The management committee now consists of Mr. Zhou Qin, Mr. Li Jia, and Ms. Li Lei, with their term aligned with the duration of the employee stock ownership plan [1] - Mr. Zhou Qin has no affiliations with the company's major shareholders or management, ensuring no conflicts of interest [1]

General Provisions - The company establishes a management system for the resignation of directors and senior management to promote healthy and sustainable development [1] - Applicable personnel include directors (including independent directors), the president, vice presidents, financial officers, board secretaries, and other senior management recognized by the company's articles of association [1] Resignation Circumstances and Procedures - Directors and senior management can resign before their term ends, with the resignation effective upon notification to the company [2] - The company must complete the election of new directors within sixty days of a resignation to ensure compliance with legal and regulatory requirements [2] - Resignation procedures include a handover of responsibilities and an internal audit before leaving [2][3] Responsibilities and Obligations of Resigning Directors and Senior Management - Resigning directors and senior management remain liable for their duties performed during their tenure, and their obligations regarding confidentiality and commitments continue post-resignation [3][4] - The company must pursue accountability for any violations of commitments or actions that harm the company's interests [3][4] Shareholding Management of Resigning Directors and Senior Management - Directors and senior management are prohibited from transferring their shares for six months after resignation [4][5] - There are restrictions on the percentage of shares that can be transferred annually during and after their term [4][5] Accountability Mechanism - The board of directors will review and determine accountability measures for any resigning directors or senior management who fail to fulfill their commitments [6] - Resigning individuals can appeal the accountability decisions within fifteen days of notification [6] Supplementary Provisions - Any matters not covered by this system will follow relevant laws, regulations, and the company's articles of association [6]

证券代码：002019 证券简称：亿帆医药 公告编号：2025-052 亿帆医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）第八届董事会任期已届满，根 据《公司法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律 监管指引第1号—主板上市公司规范运作》等相关法律法规、规范性文件及《公 司章程》的有关规定，经公司第八届董事会提名委员会资格审查，公司于2025 年8月13日召开第八届董事会第十八次会议，审议通过了《关于董事会换届选举 非独立董事的议案》《关于董事会换届选举独立董事的议案》，现将具体情况公 告如下： 一、董事会换届选举情况 根据《公司法》和《公司章程》的相关规定，公司第九届董事会由6名董事 组成，其中非独立董事3名，独立董事2名，职工代表董事1名。 经公司第八届董事会提名委员会资格审查，第八届董事会第十八次会议审议， 董事会同意提名程先锋先生、林行先生、冯德崎先生为公司第九届董事会非独立 董事候选人；提名曾玉红女士、刘梅娟女士为公司第九届董事会独立董事候选人。 上述简历详见下文附件。 ...

Core Viewpoint - Yifan Pharmaceutical Co., Ltd. has nominated Liu Meijuan as a candidate for the independent director of its ninth board of directors, ensuring compliance with relevant regulations and qualifications for independent directors [1][8]. Summary by Sections Nomination Process - The nomination of Liu Meijuan was made after a thorough review of her professional background, education, qualifications, and any potential conflicts of interest [1]. - The nominee has agreed in writing to serve as an independent director candidate [1]. Compliance with Regulations - The nominee meets the qualifications and independence requirements set forth by the Company Law of the People's Republic of China and the Shenzhen Stock Exchange [1][2]. - The nominee has participated in training and obtained relevant certification recognized by the stock exchange [2]. Independence Assurance - The nominee does not have any close relationships that could affect her independent performance [1]. - The nominee and her immediate family do not hold more than 1% of the company's issued shares and are not part of the top ten shareholders [5][6]. Commitment to Responsibilities - The nominator guarantees the truthfulness and completeness of the statements made regarding the nominee's qualifications [8]. - The nominator commits to report any changes in the nominee's independence status during her tenure as an independent director [8].